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Introduction. Many years of experience of domestic phy-
tochemical production does not diminish the urgency and 
importance of the problem of standardization and quality 
control of both phytopreparations and medicinal plant raw 
materials, which is the source of their production. The 
composition of biologically active substances (BAAs) con-
tained in medicinal plant raw materials may vary during the 
process of plant growth, harvesting, drying and storage, 
transportation, method and apparatus to obtain them, so 
control of critical parameters at each stage is important and 
requires the use of new approaches. 
Based on the concept of harmonization of the na-
tional legislative framework for quality control of medici-
nal products with the European Pharmacopoeia (EP), the 
relevant articles of the EP are used as a basic document in 
the development of the articles of the State Pharmacopoeia 
of Ukraine. The following general articles are listed in the 
General Monographs section of the EP: “Medicinal Herbal 
Products”, “Medicinal Herbal Raw Materials” and “Medic-
inal Herbal Teas” [1].  
Currently, in Ukraine, the quality of herbal reme-
dies and raw materials is governed by the following general 
monographs of SPhU: “Medicinal Herbal Raw Materials”, 
“Medicinal Herbal Remedies”, “Medicinal Herbal Spe-
ciesN”, “Medicinal Herbal Teas”, and “Medicinal Herbal 
Teas, Soluble” [2]. 
Manufacture of medicines in the European Union 
is carried out in accordance with the requirements of Good 
Manufacturing Practice (GMP). The quality of herbal me-
dicinal products and their differences with medicinal prod-
ucts containing active substances with a defined chemical 
structure are set out in Directive 75/318 / EEC as amended. 
At present, the range of medicines for the treat-
ment of mastopathy is represented, for the most part, by 
foreign manufacturers, which are currently not economi-
cally available to the general population of Ukraine. The 
structure of the range of drugs used in mastopathy therapy 




Fig. 1. Market structure of medicines used in mastopathy therapy by country of origin 
 
Almost 44% of the assortment is domestic prod-
ucts. That is, drugs that provide both physical (availability 
at the place of sale of the drug) and economic affordability 
(the price of the drug suits the consumer) [3, 4]. 
Given the need to implement the principles of im-
port substitution, the development of original domestic 
preparations based on medicinal herbs for the treatment of 
mastopathy is relevant. 
The use of standardized drugs based on medicinal 
plant raw material (MPRM) will allow more comprehen-
sive coverage of all links in the pathogenetic picture of 
mastopathy, reduce the dose of synthetic chemotherapy 
and pay more attention to quality rehabilitation of women, 
while maintaining their health and reproductive function 
[5, 6]. 
The importance of the above has led to the devel-
opment of a new drug in the form of species for use in gy-
necology. Based on the results of pharmaco-technological, 
physicochemical, biopharmaceutical studies, the composi-
tion of the medicinal herbal product was selected. The de-
velopment used medicinal plant raw materials, approved 
for medical use by the Ministry of Health of Ukraine and 
containing phytohormones - biologically active sub-
stances, capable of correcting the hormonal level - hop 
cones, parsley sowing leaves, stevia honey grass. Due to 
the multisymptomatic course of mastopathy, vitamins and 
raw materials were added to the collection, which strength-
ens the immune status of the organism: nettle leaves, com-
mon cranberries and dog rose hips. Excess of sex hormones 
has a negative impact, therefore, patients are usually pre-
scribed hepatoprotectors, the purpose of which is to stimu-
late the function of hepatocytes and normalize intracellular 
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metabolism of phospholipids. To improve the metabolism 
of hormones in the liver and excretion of products of their 
metabolism we used MPRM, which has a choleretic and 
diuretic effect: corn columns with receptacles, field horse-
tail grass [7, 8]. 
The pharmaceutical market of Ukraine has no an-
alogues of standardized medicinal herbal species for com-
plex treatment of mastopathy, but the available compo-
nents have long been used in folk medicine [9].  
 
Material & methods. According to the results of pharma-
cotechnological studies, a technological scheme for obtain-
ing non-dosed and dosed species was developed (Figs. 2 – 
3).  
 
Results & discussion. “Mastonorm” species technology in-
cludes the following stages of the production process: 
• Preparation of medicinal plant raw materials. 
• Production of “Mastonorm” species. 
• Filling, packing and marking of “Mastonorm” species. 
• Filling, packing and labelling of “Mastonorm” species in 
filter bags 
Only raw materials, packaging materials and 
printed matter that have been subjected to incoming quality 
control in accordance with the specifications of the input 
control and are allowed to use for the production of “Mas-
tonorm”. Stage 1 is carried out in the premises of weighing 
plant raw materials, which according to the technical regu-
lations refer to unclassified with controlled parameters.  
 
Stage 1  
Preparation of medicinal plant raw materials 
Plant raw materials used for the preparation of the 
drug must be subject to input control for compliance with 
regulatory requirements. After passing the input control, 
raw materials are given the status of "Permitted for use" 
and labelled with appropriate labels. Raw materials in bags 
or boxes are transported by means of transport carts from 
the stock of vegetable raw materials No. 1 to the premises 
of weighing of raw materials. Raw materials are viewed on 
the table. They reject mouldy raw materials, foreign ob-
jects, minerals (stones, earth, etc.) and organic (parts of 
plants of other species, pieces of rope, etc.) impurities. Dis-
carded raw materials and impurities are collected in bags 
or plastic boxes (containers) for waste. The revised raw 
material is collected in bags or plastic boxes (containers) 
for raw material and weighed by weights according to the 
material balance of the batch in the following quantity: 
On the bags / containers with weighed raw mate-
rials they affix identification labels, which indicate: the 
name of the preparation, batch, date, name of the raw ma-
terial, quantity of raw material, shelf life, name and signa-
ture of the executor. With the transport trolleys, bags / con-




Production of “Mastonorm” species 
Stage 2 is carried out in a room that is classified 
as unclassified one with controlled parameters. Before the 
start of stage 2, check the proper preparation of the prem-
ises, technological equipment, auxiliaries and materials 
(the presence of identification labels, preparation proto-
cols) with an appropriate mark in the production protocol 
of the preparation. 
Transportation of raw materials within the site is 
carried out by means of transport carts. The waste gener-
ated during Stage 2 is collected, accounted, stored and dis-
posed. 
Medicinal plant raw material is manually loaded 
into the mixer. After loading on the mixer attach the label 
"In Work" (on the label indicate: the name of the drug, 
batch, date, total amount of raw material, position, name 
and signature of the performer) and stir the raw material for 
50 ± 5 min. The rotation speed of the mixer drum is 15 – 
20 min-1. Prepared unpacked “Mastonorm” species (a mix-
ture of pieces of various shapes with inclusions of dark red 
in different shades, the smell is slightly aromatic) is un-
loaded by gravity into mobile collectors. 
In weighing scales consistently, collectors 
weighed and verified the total weight of unpackaged spe-
cies “Mastonorm”. An identification label is affixed to 
each collector. 
Collectors with the “Mastonorm” collection are 
handed over to the premises for packing the species for 
Stage 3 - the filling, packaging and marking of the “Mas-
tonorm” species. The finished product series is formed 
from a single mixer load. 
 
Stage 3.  
Filling, packing and marking of “Mastonorm” species  
100.0 g species in plastic bags enclosed in cardboard packs; 
100.0 g species per pack based on aluminum foil; 
100.0 g species in “Doy-packs” 
Stage 3 is spent indoors species packing facilities 
that are classified as unclassified room with controlled pa-
rameters. 
Before the start of stage 3, check the proper prep-
aration of the premises, technological equipment, auxilia-
ries and materials (the presence of identification labels, 
preparation protocols) with a corresponding mark in the 
production protocol of the preparation. 
Transportation of materials within the site is car-
ried out by means of transport carts. Waste arising from the 
operations of Stage 3 is collected, accounted for, stored and 
disposed of in accordance with the enterprise standard. 




Medicinal plant raw materials used for the prepa-
ration of the drug must be subject to input control for com-
pliance with regulatory requirements. After passing the in-
put control, the materials are given a "Permitted to Use" 
status and labelled with appropriate labels. The primary 
packaging materials are delivered to the site from a stock 
of consumables. 
Non-dosed species "Mastonorm" is manually 
packed into plastic bags of 100.0 g by weight. The collect-
ing packs are sealed on the table with a pulse sealer. During 
the packing and sealing process, they visually check the 
appearance of the package and reject the packages with de-
fects. The collection of discarded packages is returned for 
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re-packaging into new plastic bags, and the damaged pack-
ages are placed in plastic waste bins (containers). 
The sealed packets with “Mastonorm” species are 
transmitted through the transfer window to the table for the 
collection packing operation. 
Remains of unused plastic bags are returned to the 
consumable warehouse and form the act of transfer. Dis-
carded packets are transferred for further disposal and con-





Fig. 2. Technological schemes of receiving the «Mastonorm» species in aluminium foil packs, polyethylene and “Doy-
packs” and 1.5 g filter packs 
Species packing and labelling Materials for primary packaging (plastic bags), 
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secondary packaging (packs of cardboard), group packag-
ing (boxes of corrugated cardboard), sticker (logo) must be 
subject to input control for compliance with regulatory re-
quirements. After passing the input control, the materials 
are given a "Permitted to Use" status and labelled with ap-
propriate labels. 
The secondary packaging material (packs of card-
board) is labelled with a batch number and a shelf life and 
sent to the site. Bulk packing materials (corrugated card-
board boxes and group labels), sticker (logo) are delivered 
to the site from a stock of consumables. 
Before packing, the cardboard boxes and packs 
are inspected and manually collected on the table. Non-
glued bundles, deformed bundles / boxes with defective 
prints are rejected. The discarded bundles are placed in 
plastic waste bins (containers) and the discarded bins are 
placed on pallets in the waste area. The collected packs are 
placed in plastic boxes (containers) for the collected packs, 
which together with the collected boxes are stored until the 
beginning of the packaging process in the area for prepared 
materials. 
On the table, packaged species is manually loaded 
into packs of cardboard and on the upper valve of the pack 
in the centre, paste a sticker and logo of the enterprise. The 
upper and lower valves in the centre are glued with a nar-
row adhesive tape. The packs with species are stacked 48 
pieces in boxes of corrugated cardboard and glued with a 
wide adhesive tape. Apply a group label of approved sam-
ple to the boxes. Boxes with finished product with the help 
of transport trolleys are transferred to the material gateway. 
“Mastonorm” species is transferred from the ma-
terial gateway to the warehouse of finished goods in the 
quarantine area. The drug series gives the status "Quaran-
tine". 
An average finished product sample is selected 
for analysis on compliance with the requirements of the 
QCP for “Mastonorm” species. After receiving positive re-
sults of the analysis of the batch of the drug are given the 
status of "Approved for sale" and transferred to the area of 
primary storage. 
Finished products are stored in accordance with 
the enterprise standard. Remains of unmarked printed 
products are returned to the consumables warehouse and 
form the act of transfer. Discarded printed products and 
remnants of the labelled printed products are transferred for 
further disposal and constitute an act of transfer. 
The following are only the features of species in 
other types of packaging. 




Un-dosed species "Mastonorm" is packed up to 
100.0 g in a material combined film on the basis of alumin-
ium foil by means of a packing machine. Before packing, 
and periodically during the shift, check the mass of the col-
lection in the package by weighing 100 ± 4 g. 
During the packing process, they visually check 
the appearance of the package: reject packages with defects 
and packages with fuzzy marking on the batch and shelf 
life. The sealed packets with “Mastonorm” species are 
transmitted through the transfer window to the table for op-
eration - packing and marking species. 
 
100.0 g species in “Doy-packs” 
Species packing 
Non-dosed species "Mastonorm" is packed up to 
100.0 g in packages "Do-pack" by means of packing instal-
lation. Before packing, and periodically during the shift, 
check the mass of the species in the package by weighing 
100 ± 4 g. 
It is allowed to store the prepared raw material for 
not more than 48 hours in a special zone in the warehouse 
of medicinal plant raw materials No. 1, designated as the 
“Prepared Raw Material Zone”, with an air humidity of not 
more than 60% and a temperature not exceeding 25 ° C. 
 
Stage 3*  
Filling, packing and labelling of “Mastonorm” species 
in filter bags 
The technology of manufacturing the “Mas-
tonorm” species up to the stage of filling, packing and 
marking of the “Mastonorm” species in filter packages is 
carried out similarly to the production of a 100.0 dosage. 
Preparation of process equipment for operation 
(scales, automatic packing machine, cellophane packing 
machine) and its operation are carried out in accordance 
with the requirements and provisions of the technical reg-
ulations and operating instructions. 
Before the start of stage 4, check the proper prep-
aration of the premises (absence of pre-production, docu-
ments and materials not required for the process), techno-
logical equipment, auxiliaries and materials, the presence 
of identification labels with a corresponding mark in the 
production protocol of the preparation. 
 
Species packing 
Primary packaging material (heat-sealing filter 
paper and aluminium foil film-based material) must be sub-
ject to input controls for compliance with regulatory re-
quirements. After passing the input control, the material is 
given a “Permitted Use” status and labelled with appropri-
ate labels. 
The primary packaging material is delivered to 
the site from the consumable warehouse via a material 
gateway. 
On the automatic tea packaging machine affix the 
label "In work" (the label indicates: the name of the drug, 
series, date, position, name and signature). The batch num-
ber and shelf life of the automatic tea packaging machine 
shall be determined in accordance with the instruction 
manual of the automatic tea packaging machine.  
Non-dosed species "Mastonorm" is packed up to 
1.5 g into filter bags from filter thermal welding paper, 
which is sealed into the material by a combined film based 
on aluminium foil on an automatic packaging machine. Be-
fore packing, and periodically during the change, check the 
mass of the collection in the package by weighing 1.5 ± 0.2 
g. 
During the packing process, the welding temper-
ature of the filter paper (120 - 125 ° C) and the temperature 
of the welding of the combined film material (100 - 105 ° 
C) are monitored at least once per hour. 
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At least once an hour visually check the quality of 
seam welding of the outer and inner packages, the presence 
of a cut on the outer package, the quality of the marking of 
the series and expiration date. Poor packages are rejected. 
The collection of all discarded packages is col-
lected in plastic boxes (containers) for collection unpacked 
and returned for re-packaging in new packages, and the 
damaged packages are placed in plastic boxes (containers) 
for waste. The discarded packets, after completion of the 
packing process, are transferred for further disposal and 
constitute an act of transfer. The remnants of the packaging 
material (filter paper, combined film material) are returned 
to the consumable warehouse and form the act of transfer. 
The sealed packets with the “Mastonorm” species 
are transmitted through the transfer window to the table for 
operation - packing and marking the species. 
 
Species packing and labelling 
Secondary materials (cardboard packs and poly-
propylene film) and group packaging (corrugated card-
board boxes) must be subject to input controls for compli-
ance with regulatory requirements. After passing the input 
control, the materials are given a "Permitted to use" status 
and labelled with appropriate labels. 
The secondary packaging material (packs of card-
board) is labelled with a batch number and a shelf life and 
transmitted to the site via the material gateway. 
Bulk packing materials (corrugated cardboard 
boxes and group labels) are delivered to the site from the 
consumables warehouse via a material gateway. 
Before packing, cardboard boxes and boxes are 
examined and manually collected on the table. Badly glued 
bundles, deformed bundles / boxes, and bundles / boxes 
with defective prints are rejected. The discarded bundles 
are placed in plastic waste bins (containers) and the dis-
carded bins are placed on pallets in the waste area. The col-
lected packs are placed in plastic boxes (containers) for the 
collected packs, which together with the collected boxes 
are stored until the beginning of the process of packing in 
the area for prepared materials. 
On the table, packaged species in packages, man-
ually put in packs of cardboard for 20 pieces. Packs of 
packets are sealed in a polypropylene film using a cello-
phane packing machine. During the sealing process, the 
welding temperature (125 - 130 ° C) and the heat shrinkage 
temperature of the polypropylene film (120 - 125 ° C) are 
monitored, and the quality of the bundle sealing is visually 
checked. 
On the table, packs wrapped in film are packed 
with 36 pieces in boxes of corrugated cardboard and glued 
with a wide adhesive tape. Apply a group label of the ap-
proved sample to the boxes. In Ukrainian, the country of 
origin, the city and name of the enterprise, its trademark 
and address, the name of the preparation in Latin and 
Ukrainian, the surname or number of the packer, the batch 
number, the number of packages shall be indicated. Boxes 
of finished product with the help of transport trolleys are 
transferred to the material gateway. 
Conclusions 
1. The technology of “Mastonorm” species was devel-
oped. 
2. The technological scheme of obtaining “Mastonorm” 
species in industrial conditions was developed. 
3. The technological industrial regulation of production 
of the “Mastonorm” species in different types of packing 
has been developed: plastic bag enclosed in cardboard 
packs; aluminium foil packs; “Doy-packs” and filter pack-
ages of 1.5 g № 20. 
 
Development of technology of plant species for com-
plex mastopathy therapy 
Zuikina S. S., Vyshnevska L. I. 
Introduction. At present, the range of medicines for the 
treatment of mastopathy is represented, for the most part, 
by foreign manufacturers, which are currently not eco-
nomically available to the general population of Ukraine. 
Structure of the range of medicines used in mastopathy 
therapy, by country of origin. Almost 44% of the assort-
ment is domestic products. That is, these drugs provide 
both physical (availability at the place of sale of the drug) 
and economic affordability (the price of the drug suits the 
consumer). Given the need to implement the principles of 
import substitution, the development of original domestic 
preparations based on medicinal herbs for the treatment of 
mastopathy is relevant. The use of standardized drugs 
based on medicinal plant raw materials (MPRM) will al-
low more comprehensive coverage of all pathogenetic 
mastopathy pathways, reduce the dosage of synthetic 
chemotherapy drugs, and pay more attention to the quality 
of women's rehabilitation while maintaining their health 
and reproductive function. The importance of the above 
has led to the development of a new drug in the form of 
collection for use in gynaecology, which includes various 
types of MPRM, capable of effectively acting on all the 
etiological and pathogenic links of mastopathy. The phar-
maceutical market of Ukraine has no analogues of a 
standardized herbal remedy for complex treatment of 
mastopathy, but the available ingredients have long been 
used in folk medicine. Material & methods. Based on 
the results of pharmaco-technological studies, a techno-
logical scheme of obtaining non-dosed and dosed species 
for use in the complex treatment of mastopathy was de-
veloped. Results & discussion. The main stages of the 
process of collecting and the critical parameters that are 
monitored at each stage are identified. The technology of 
collecting in different types of packing is described: in al-
uminium foil packs, plastic bags and “Doy-packs” and fil-
ter bags.Vegetable raw materials used for the preparation 
of the drug must be subject to input control for compli-
ance with regulatory requirements. “Mastonorm” species 
technology includes the following stages of the produc-
tion process: preparation of medicinal plant raw materials, 
production of “Mastonorm” species, weighting, packag-
ing and marking of the “Mastonorm” species. For dis-
pensing, there is a step of filling, packing and labelling 
“Mastormorm” species into filter bags.  
Conclusion. The technology of “Mastonorm” species was 
developed. The technological scheme of obtaining “Mas-
tonorm” species in industrial conditions was developed. 
The technological industrial regulation of production of 
the “Mastonorm” species in different types of packing has 
been developed: plastic bag enclosed in cardboard packs; 
aluminium foil packs; “Doy-packs” and filter packages of 
1.5 g № 20. 
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